Capital Markets Event: View a recording and access materials presented at OXB’s Capital Markets Event held on 2nd June 2026.

VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category.

Enhanced Transcriptional Insulation of Lentiviral Vectors using “Sequence Upgraded polyA Long Terminal Repeats” or “supA-LTRs”

June 1, 2026